Cramer's Lightning Round: Albemarle is 'too volatile'
Astera Labs: "It's too hot for me."
Equinix: "Equinix is still too expensive."
Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest smarter.Disclaimer
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
4 hours ago
- CNBC
Brinker International CEO on marketing success: It's relevant to people's lives and it's working
Brinker International CEO Kevin Hochman joins 'Mad Money' host Jim Cramer to talk Q2 earnings, social media marketing and the state of the consumer.
Yahoo
5 hours ago
- Yahoo
Jim Cramer on Eli Lilly Stock: 'It Just Got Pole-Axed, Laid to Waste'
Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer commented on. Cramer highlighted the reasons behind the stock's decline recently. He remarked: 'Last and least, I look at the drug stocks and I can't believe how awful they really are, with now Eli Lilly last joining the ugly fray with its less than impactful, less thought weight loss, the pill. The Street was hoping that Lilly would be able to replace its onerous GLP-1 injection with a simple pill that would produce an equal amount of weight loss. No such luck. The stock, it just got pole-axed, laid to waste.' Pixabay/Public Domain Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceuticals for diabetes, obesity, cancer, autoimmune conditions, neurological disorders, and other diseases. The company's portfolio includes treatments across multiple therapeutic areas. In a July episode, Cramer mentioned the company and said: 'What I'm thinking, as someone who owns Eli Lilly for the Charitable Trust and who wishes I owned PepsiCo, is that there might be a short-term peak in the use of these drugs (GLP-1s). The Achilles heel of these drugs is that they're too effective. At some point, you lose enough weight, and you might think you can stop taking them… Whatever the case, if Eli Lilly is going to break out from this level, it needs breakthroughs in new areas, heart, brain, that it just doesn't have right now, or there has to be some new data that shows something else positive that the GLP-1 drugs can do. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
8 hours ago
- CNBC
Lightning Round: Arcus Biosciences is speculative, it's too risky to fully bank on, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Arcus Biosciences and Uranium Energy.
